Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05210439 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of 7 Versus 14 Days of Antibiotic Treatment for Pseudomonas Aeruginosa Bacteraemia

Study acronym: SHORTEN2
StatusActive, Not Recruiting
PhasePhase 4
Started2022-04-28
View on ClinicalTrials.gov ↗

Amendment history

2026-01-20
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v7
Trial statusRecruiting→Active, Not Recruiting
Primary completion dateestimated 2025-06→confirmed 2025-12-01
Completion date2025-09→2026-06
Study sitesdetails revised at 37 of 37 sites
2024-06-19
Study Status, Outcome Measures, Contacts/Locations v6
Secondary endpointsdetails revised at 1 of 8 entries
Study sitesdetails revised at 1 of 37 sites
2024-03-01
Study Status, Contacts/Locations, References v5
Study sites30→37
Publicationsdetails revised at 1 of 1 entry
2023-05-03
Study Status, Contacts/Locations v4
Study sitesdetails revised at 24 of 30 sites
2022-05-20
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v3
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2022-04→confirmed 2022-04-28
Study sitesdetails revised at 30 of 30 sites
Show 2 earlier versions
2022-04-12
Study Status, Eligibility, Contacts/Locations v2
Eligibility criteria+8 characters
[...] nformed consent signed. Main exclusion criteria: Bacteremia focussource not adequately controlled at least 72h before randomization. Bacteremia secondary to an infection that nec [...] n at the time of diagnosis of bacteremia that also requires prolonged antibiotic treatment. Bacteremic pneumonia in severely immun [...]
Study sitescontacts updated at 1 of 30 sites
2022-03-31
Study Status v1
Start date2022-02→2022-04
2022-01-14
Original filing
Phase IV, open-labeled, randomized and multicenter clinical trial to demonstrate the superiority of antibiotics with authorized indication for 7 days versus 14 days in the treatment of bloodstream infections produced by P. aeruginosa (BSI-PA).
Trial Details
NCT Number NCT05210439
Lead Sponsor Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Collaborators: Spanish Clinical Research Network - SCReN, Centers for International Business Education and Research
Conditions Bloodstream Infection
Enrollment 306 participants
Start Date 2022-04-28
Primary Completion 2025-12-01 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-01-22